Titan Pharmaceuticals INC: directors' dealings · United States · SEC (Form 4)

About Titan Pharmaceuticals INC

Titan Pharmaceuticals Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ market in the United States. For investors, it should be viewed primarily as a micro-cap healthcare name built around a proprietary long-acting drug delivery platform rather than as a diversified commercial pharma group. The company was incorporated in Delaware in 1992 and its operating headquarters have been in South San Francisco, California; recent SEC filings also list its business address at 400 Oyster Point Blvd, Suite 505. Titan’s business model has historically centered on a small number of science-driven assets with meaningful regulatory and financing risk. ([titanpharm.com](https://www.titanpharm.com/about?utm_source=openai)) The company’s core technology is ProNeura®, a subdermal implant platform designed to deliver medicine continuously and at stable levels over extended periods. The platform is intended for chronic diseases where maintaining steady drug exposure may improve efficacy, safety, or adherence. Titan’s first product built on ProNeura was Probuphine® (buprenorphine implant), used for maintenance treatment of opioid use disorder in clinically stable patients. Titan previously obtained approvals in the United States, Canada, and the European Union, but it later discontinued U.S. commercialization of Probuphine and sold the product in September 2023. That transition materially changed the company’s profile from a commercial-stage story to a more development-focused biotech. ([titanpharm.com](https://www.titanpharm.com/about?utm_source=openai)) From a competitive standpoint, Titan is best described as a niche platform company rather than a scale player. Its differentiation lies in implantable drug-delivery know-how, intellectual property, and the potential to apply ProNeura to chronic conditions requiring long-duration treatment. Beyond Probuphine, Titan has pursued additional pipeline opportunities around ProNeura, including a nalmefene implant program supported in part by the National Institute on Drug Abuse, as well as earlier work in areas such as chronic pruritus. The company also undertook a strategic restructuring to narrow its focus, reduce operating costs, and preserve capital, which is consistent with the economics of a small biotech platform company. ([ir.titanpharm.com](https://ir.titanpharm.com/press-releases/detail/251/titan-pharmaceuticals-reports-third-quarter-2020-financial)) Geographically, Titan’s footprint is overwhelmingly U.S.-centric, with international exposure historically linked to European commercialization of Sixmo, the EU brand for Probuphine. Recent SEC disclosures confirm its U.S. biotech classification and ongoing reporting status. On recent developments, SEC filings in 2025 show the company remained active on the regulatory reporting front, while a merger / restructuring process announced in 2024-2025 represents a key corporate event that could alter the listed structure and investor base. For equity investors, that makes Titan a name to watch not only for clinical and operational updates, but also for Form 4 insider activity and transaction-driven corporate developments. ([sec.gov](https://www.sec.gov/Archives/edgar/data/910267/000182912625003656/0001829126-25-003656-index.html))